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Abstract
Renal angiomyolipomas are found in up to 80% of tuberous sclerosis complex (TSC) patients. Although these tumours are
usually asymptomatic, lesions >3 cm in diameter are prone to bleeding and up to 10% of TSC patients may experience a
massive and potentially fatal retroperitoneal haemorrhage. Diagnosis can be complicated because of the initial lack of
symptoms and the fat-poor content of atypical renal angiomyolipomas. After diagnosis, tumour growth and the emergence
of new tumours must be monitored. Treatment with mammalian target of rapamycin (mTOR) inhibitors can reduce tumour
size and is indicated in patients with TSC-associated renal angiomyolipomas >3 cm in diameter. Imaging-based
assessment of kidney disease is essential to the diagnosis and management of patients with TSC. The aims of imaging
studies in this context are to detect and characterize tumours, assess and detect the risk of complications and evaluate the
response to treatment, especially in patients treated with mTOR inhibitors. A multidisciplinary expert panel developed a
series of recommendations based on current evidence and professional experience for imaging studies in adults and
children with TSC-associated renal angiomyolipoma. The recommendations cover radiological diagnosis and follow-up of
the classic and atypical or fat-poor TSC-associated renal angiomyolipomas, biopsy indications, minimal requirements for
radiological requests and reports and recommended technical features and protocols for computed tomography and
magnetic resonance imaging.
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Introduction
Tuberous sclerosis complex (TSC) is a rare hereditary disease
caused by mutations of the TSC1 or TSC2 genes [1] that are related
to the PI3K/AKT/mTOR signalling pathway. These mutations
induce overactivation of mammalian target of rapamycin (mTOR)
protein, which in turn induces uncontrolled cell growth [2]. TSC is
characterized by benign tumours that can develop in multiple
organs, including the skin, brain, kidneys, liver, lungs and heart [3].
However, it is an extremely variable disease, with multiple and
unspecific clinical manifestations that can differ in severity accord-
ing to the patient’s age and the stage of life at onset. Furthermore,
TSC requires continued surveillance to monitor known manifesta-
tions and identify any potential new ones [1].
The most common renal manifestations of TSC are angio-
myolipomas, which are found in up to 80% of TSC patients [4];
the presence of two or more renal angiomyolipomas is a major
diagnostic criterion for a TSC diagnosis [5]. Another frequent
kidney lesion in TSC is renal cysts, which are found in 14–32% of
patients [6].
TSC-associated renal angiomyolipomas are usually multiple,
bilateral and asymptomatic until there is irreversible renal dam-
age or bleeding. They are more prone to bleeding and growth
than sporadic angiomyolipomas, which are generally smaller
and solitary [7, 8]. Diagnosis and follow-up of TSC-associated
renal angiomyolipomas are based mainly on imaging studies.
Although renal angiomyolipomas are still the main cause of
morbidity and mortality in adults with TSC [4], mTOR inhibitors
can reduce the size of angiomyolipomas and have become first-
line therapy for tumours with diameters >3 cm [5]. There are no
controlled trials comparing therapy with mTOR inhibitors and
embolization to prevent bleeding and recurrence and preserve
renal function [9]. However, mTOR inhibitors are recommended
for pre-emptive treatment, while embolization should be
reserved for acutely bleeding tumours [5] since this technique
leads to loss of kidney parenchyma [10].
Radiological assessment of kidney disease in TSC patients is
essential to the diagnosis and management of the disease in
terms of both treatment and follow-up. Given the lack of
imaging-based recommendations for the diagnosis and man-
agement of TSC-associated angiomyolipoma, a multidiscipli-
nary expert panel developed a series of recommendations
based on current evidence and their professional experience for
imaging-based management of patients with TSC-associated
renal angiomyolipoma.
Imaging technologies in TSC-associated renal
angiomyolipoma
The aims of imaging studies in TSC-associated renal angiomyo-
lipomas are to detect and characterize tumours, to assess and
detect the risk of complications (especially bleeding) and to
evaluate the response to medical and surgical treatment.
The three currently available technologies for the study of TSC-
associated renal tumours are ultrasound, computed tomography
(CT) and magnetic resonance imaging (MRI). See Supplementary
data for technical features and recommended protocols.
Ultrasound
Ultrasound is a useful initial approach to determine whether kid-
ney lesions are present and whether these are cystic or solid.
Contrast-enhanced ultrasound is not recommended, owing to its
lack of reproducibility and the difficulty in analysing multiple
lesions in a single scan. In the case of simple cysts, ultrasound
may be sufficient. However, if the content of the lesions is not
completely anechoic or the lesions have thick septa or solid
poles, further study with CT or MRI is needed [11–13]. MRI and CT
can differentiate between infected or bleeding cysts and solid
tumours [14]. Renal angiomyolipomas usually appear as hyper-
echoic solid lesions, but their echogenicity may vary depending
on the amounts of fat, muscle or vessels that constitute the
lesion.
CT
CT has higher precision and reproducibility than ultrasound,
minimizing inter- and intra-observer variability, therefore CT
is the recommended technique in most cases. Moreover, it is
the preferred technique for pre-surgical mapping prior to embo-
lization or resection. However, its use in the diagnosis and
follow-up of young patients is limited by the accumulation of
radiation [15].
Intravenous administration of contrast media is necessary to
achieve good definition of the lesions, to differentiate angiomyo-
lipomas from other tumours and to perform CT angiogram and
vascular mapping that may be useful in patient management. A
glomerular filtration rate (GFR) <45 mL/min/1.73 m2 is a relative
contraindication to the use of intravenous iodinated contrast
media; however, if necessary, prophylaxis against contrast-
induced nephropathy can be administered [16].
An additional basal non-enhanced CT (NECT) will be helpful
in cases of haemorrhage. By itself, NECT is of limited usefulness
because it only distinguishes between fat and non-fat compo-
nents (which include tumour as well as renal cortex). It will be
used only in patients in which intravenous contrast cannot be
administered and MRI cannot be performed. CT-induced
adverse events and contrast reactions are more frequent than
in MRI, as is nephrotoxicity [16].
MRI
A minimum of 1.5 T is required for MRI scanners. MRI does not radi-
ate and thus enables good characterization of lesions. Its spatial res-
olution is lower than that of CT, whose fast speed avoids artefacts
caused by abdominal movements that blur lesions and organ con-
tours on the MRI, even with higher-strength fields. However, MRI is
sufficient to assess the size of angiomyolipomas and other renal
lesions associated with TSC, even without contrast.
Sometimes contrast is needed for better definition of angio-
myolipomas and the differential diagnosis between fat-poor
angiomyolipomas and other renal tumours. Enhanced MRI
has worse spatial resolution of the abdomen than CT, but it is
useful for measuring microaneurysms, especially in patients
with allergy to iodinated contrast or with a GFR between 30
and 45 mL/min/1.73 m2. Enhanced MRI is also useful in
routine controls or treatment follow-up. If the GFR is <30 mL/
min/1.73 m2, gadolinium is contraindicated due to an increased
risk of nephrogenic systemic fibrosis [17]. Table 1 summarizes
the advantages and disadvantages of the different imaging
technologies.
Diagnosis of angiomyolipoma
Imaging-based diagnosis of angiomyolipoma
Angiomyolipoma is a triphasic tumour composed of fat, smooth
muscle and blood vessels in variable proportions [18] (Figure 1).
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Renal angiomyolipomas are classified into classic and atypical
types according to their imaging features.
Classic renal angiomyolipomas
Classic renal angiomyolipomas can be found in up to 80% of
TSC patients and are more frequent with increasing age. Fat is
one of their major components and macroscopic adipose tissue
can be seen in most cases (Figure 1).
Ultrasound shows them to be hyperechoic and usually
homogeneous. Exophytic renal angiomyolipomas may be hid-
den by perirenal fat. The whole kidney should be scanned in the
axial and coronal planes to visualize areas potentially hidden by
rib shadows or colonic gas.
On CT, they are seen as assorted morphological masses.
They can be numerous with diffuse margins. However, macro-
scopic fat with negative densitometric values (attenuations
<10 HU) is always seen, as are non-fat components with
enhancement in the early arterial phase and other smooth
muscular components that are solid with lower enhancement.
The standard recommended study protocol with sections of
3 mm and reconstruction of 1.5 mm provides well-defined
images of the abdomen and pelvis, making it possible to detect
small amounts of fat that would not be seen in thicker sections.
Very small regions of interest or even voxel values may be
required to avoid the partial volume effect [18].
Measurement of size is important because of the increased
risk of bleeding in angiomyolipomas >3 cm and in micro-
aneurysms >5 mm [19].
On MRI, a hyperintense fat component is observed on T1-
and T2-weighted images, as is a hypointense component on
T2-weighted images with fat saturation (spectral saturation is
preferable). On the dual sequence, the India ink sign, which
highlights the lesion in the out-of-phase (opposed phase)
sequence, is highly suggestive of angiomyolipoma [20].
Atypical or fat-poor angiomyolipomas
Around 5% of angiomyolipomas are atypical or fat poor, yet
they affect up to 33% of TSC patients [21]. Fat cannot be detected
with unenhanced CT where fat-poor angiomyolipomas have a
density >10 HU [18]. On MRI, there is no fat suppression on fat
saturation sequences, although it is observed in the dual out-of-
phase sequence. Even though CT and MRI are useful for diag-
nosing atypical angiomyolipomas [22–26], biopsy may be neces-
sary to complete the analysis.
There are three subtypes of atypical or fat-poor angiomyoli-
pomas: hyperattenuating, isoattenuating and angiomyolipoma
with epithelial cysts. A fourth and very rare subtype is epithe-
lioid angiomyolipoma.
The ‘hyperattenuating subtype’ is the most common fat-
poor angiomyolipoma (4–5%). It is composed predominantly of
smooth muscle cells and its fat content is low (4%). Its mean
diameter is 3 cm. Ultrasound images are unspecific with a solid,
homogeneous and muscle-isoechoic nodule. Hence diagnosis
requires CT and/or MRI [27].
Isoattenuating angiomyolipoma is very rare and its fat con-
tent is dispersed. On CT, it is isodense to muscle and has early
enhancement and fast washout (ratio arterial/late HU>1.5). On
MRI, it is hypointense on T2-weighted images. It does not
always suppress fat on fat saturation sequences, although it
typically does so on the dual out-of-phase sequence. The possi-
bility of an isoattenuating angiomyolipoma must be considered
in the presence of a renal mass that is suppressed on the out-
of-phase sequence [27].
Angiomyolipoma with epithelial cysts is also very rare,
although more common in women. It is composed of smooth
muscle and cysts, with little or no fat content. Its radiological
features are not well known [27].
Epithelioid angiomyolipoma is a singularly rare subtype of
atypical angiomyolipoma. It is usually larger than the other fat-
poor angiomyolipomas, with a mean diameter of 7 cm [28]. It
may bleed like a classic angiomyolipoma, but its import lies in
its potential malignancy with local recurrence and distant
metastasis [29]. Histologically, it can mimic other renal
tumours, such as clear cell renal carcinoma (CCRC) [30]. It has
little or no fat content and, accordingly, can be hyperattenuat-
ing on unenhanced CT and hypointense on an MRI T2 sequence.
Small fat masses can be detected in some cases. It can also
present as a solid mass with homogeneous or heterogeneous
Table 1. Advantages and disadvantages of imaging technologies in TSC-associated angiomyolipoma
Technology Advantages Disadvantages
Ultrasonography No radiation Low precision
Very accessible Poor intra- and interobserver reproducibility
Fast
Convenient for patients
CT High precision Radiation
High reproducibility Adverse events and reactions to iodinated contrast media
MRI High resolution for differentiating tissues Adverse events and reactions to gadolinium
No radiation Less spatial resolution than CT
Fig. 1. Contrast-enhanced CT scan of a right-kidney angiomyolipoma composed
mainly of adipose tissue (<10 HU).
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enhancement or as a multicystic mass [31]. Table 2 shows the
main imaging features of angiomyolipomas.
Differential diagnosis between
angiomyolipomas and other entities
The diagnosis of angiomyolipoma can only be confirmed by
means of a tumour biopsy. However, as aggressive procedures
should be avoided in TSC patients, it is preferable to first
attempt a differential diagnosis using imaging techniques.
The differential diagnosis aims to distinguish angiomyolipo-
mas from retroperitoneal extrarenal tumours and malignant
renal neoplasms. TSC-associated renal neoplasms are generally
specific subtypes, which are not very aggressive, and are found
in patients younger than the general population with renal
tumours. Fat content in a renal tumour is highly suggestive of
angiomyolipoma, especially in a patient with TSC [13, 32].
Moreover, TSC-associated renal neoplasms can mimic fat-poor
angiomyolipomas; if this is the case and a reliable diagnosis
cannot be made by imaging, a tumour biopsy is needed.
Classic angiomyolipoma
Classic angiomyolipoma should be differentiated from other
solid tumours containing macroscopic fat, mainly CCRCs and
liposarcomas, as well as other less common tumours such as
Wilms tumours and teratomas. Fat-free tumours are sometimes
embedded in fat from the renal sinus, which looks like part of
the tumour. There are no imaging-based pathognomonic signs
of angiomyolipoma, although some data highly increase the
probability of angiomyolipoma and other types of tumour.
CCRCs may contain fat, usually as a result of fat necrosis
and, like angiomyolipomas, are hyperechoic. However, ultra-
sound images can help: if the tumour is <3 cm and an acoustic
shadow is discernible, the most probable diagnosis is angio-
myolipoma, while the presence of a hypoechoic halo and intra-
tumoural cysts suggests CCRC [33]. Additionally, a tumour
treated with radiofrequency or embolization will sometimes
show a halo of fat necrosis. It is also worth noting that intratu-
moural calcifications are very suggestive of CCRC [34].
Moreover, bleeding angiomyolipomas can be mistaken for other
types of tumours because fat can be hidden by blood; a compari-
son between current and older images can prove useful in these
cases [35].
Finally, renal liposarcoma is extremely rare, but imaging
studies can help to differentiate it from angiomyolipoma. Thus,
if the feeding vessel and claw sign are present, angiomyolipoma
is highly probable [36]. Intratumoural or perirenal bleeding and
dilated or bridging intratumoural vessels are also suggestive of
angiomyolipoma [37].
Atypical angiomyolipomas
Atypical or fat-poor angiomyolipomas show lower signal inten-
sity (SI) on T2 sequences than the classic type owing to the pre-
dominance of the muscular component. Another useful finding
is a tumour/kidney SI ratio >1.2 on T2-weighted images with fat
saturation, which indicates 100% specificity for renal cell
carcinoma [13].
If imaging features are highly suggestive of fat-poor angio-
myolipoma (such as a renal mass 3 cm in diameter, hyper-
attenuating on unenhanced CT and homogeneously
enhancing for hyperattenuating subtype or a T2 hypointense
renal mass for isoattenuating subtype [18]) rather than
another tumour with a worse prognosis, the panel recom-
mends performing the same follow-up as for the classic type.
Table 3 summarizes the differential diagnosis of this type of
angiomyolipoma.
Recommendations for biopsy
There are no current statistics or solid indications to biopsy fat-
poor angiomyolipomas. The most common indications are
intratumoural calcifications, intratumoural cysts, solitary fat-
poor angiomyolipomas or any uncertain image on MRI [13], as
these features are not usually found in angiomyolipoma.
Although previously not favoured, the use of renal mass
core biopsies is increasing because of a diagnosis efficacy of
>92%, being able to differentiate between benign and malign
renal masses in most of them [38]. The reported complication
rate is 8%, with most of them having a Clavien–Dindo classifi-
cation of <2 [39].
In patients with TSC, the coexistence of classic angiomyoli-
pomas and atypical lesions is common. If MRI or the other tech-
niques are not able to differentiate between benign and
malignant masses, these atypical lesions should then be biop-
sied. If the pathology confirms a fat-poor angiomyolipoma, this
result may be extrapolated to the others (Figure 2), but close
Table 2. Types of angiomyolipoma according to their imaging featuresa
Type of angiomyolipoma Ultrasound CT MRI
Classic Hyperechoic <10 HU T2 hypointense on FS
T1 hypointense ring on OOP (in some cases)
Atypical
Fat poor
Hyperattenuating Isoechoic 45 HU on unenhanced CT Hypointense on unenhanced T1 and
T2 sequences
6 T1 suppression on OOP
Isoattenuating Slightly hyperechoic <10 to 45 HU T2 hypointense þ signal loss on FS
With epithelial cysts Unknown Hyperattenuating with cysts or
multilocular cystic
Solid component in T2 hypointense 6
signal loss on FS
Epithelioid Unknown Hyperattenuating (>45 HU) and
heterogeneous
Signal loss on FS
aBased on Yamakado et al. [19], Jinzaki et al. [27], Rosser et al. [28], Israel et al. [20] and Froemming et al. [31].
FS, frequency-selective fat suppression; HU, Hounsfield units; OOP, out-of-phase sequence.
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surveillance is needed. The need for further biopsies should be
assessed individually.
Monitoring the progression of renal
angiomyolipoma
Regular controls are needed because of the risk of haemor-
rhage associated with angiomyolipomas and the possibility of
other types of tumours. When untreated, TSC-associated
angiomyolipomas have a growth rate of 1.25 cm/year, which is
higher than that of sporadic angiomyolipomas (0.19 cm/year)
[40]. Lesions >3 cm are prone to bleeding and up to 10% of
patients may experience a massive and potentially fatal retro-
peritoneal haemorrhage [41]. Moreover, the number and size
of angiomyolipomas increases with age [42], thus exacerbat-
ing the risk of bleeding. Regular follow-up checks are also
important in angiomyolipomas with no visible fat [43].
Imaging techniques enable the identification of TSC-
associated renal angiomyolipomas with a diameter >3 cm. They
are also useful for monitoring volume reduction and stabiliza-
tion in treated patients.
Surveillance of untreated patients
As organ involvement varies according to the age of patients
with TSC, imaging follow-up protocols for children and
adults should be different [5, 43]. We offer several recommen-
dations for imaging-based surveillance of untreated TSC
patients.
Recommendations for patients <18 years of age:
• Perform ultrasound and/or MRI at the diagnosis of TSC. If
sedation is needed, the panel recommends taking advantage
of the opportunity to perform brain and abdominal MRI in
the same study. If renal lesions are detected, surveillance is
mandatory.
• Tailor surveillance according to findings.
• If an angiomyolipoma of <3 cm is detected, perform
follow-up checks every 1 or 2 years. If MRI is not needed
for neurological follow-up, ultrasound-based follow-up
of renal lesions may be acceptable. If no variations are
found, the interval between follow-up checks can be as
long as 3 years.
• If an asymptomatic angiomyolipoma of 3 cm is detected,
assess microaneurysms with CT or MRI. A decision on
treatment should be made and then assessment of the
angiomyolipoma should be made every year.
Recommendations for adults:
• For asymptomatic patients with an angiomyolipoma of
<3 cm, perform follow-up checks every 2 years using tomo-
graphic techniques, mainly MRI. If the disease is stable,
increase the interval between follow-up checks.
• For asymptomatic patients with at least one angiomyoli-
poma >3 cm, assess possible intratumoural aneurysms
using CT angiography or MRI angiography. Asymptomatic
patients should be followed up annually with MRI.
• For asymptomatic patients with atypical tumours where no
biopsy has been carried out, perform a yearly MRI follow-up
check.
• Any emergency involving lower back pain, signs of perito-
neal irritation, haematuria or hypovolemic shock denotes a
complication of angiomyolipoma. Urgent cases should be
Table 3. Differential diagnosis of fat-poor angiomyolipomasa
Subtype Differential diagnosis
Hyperattenuating RCC (papillary type)
Oncocytoma
Metastases








aBased on Siegel et al. [33], Silverman et al. [34], Schieda et al. [36], Ellingson et al.
[37], Chung et al. [13] and Jinzaki et al. [18].
bPapillary tumour is T2 hypointense as an angiomyolipoma but usually shows
late enhancement.
cBiopsy is needed. Angiomyolipoma and MEST may be positive for actin and
desmin but multilocular cystic RCC is not.
RCC, renal cell carcinoma; MEST, mixed epithelial and stromal tumour.
Fig. 2. Abdominal MRI of a female patient with TSC. Images (A) and (B) show an
angiomyolipoma with its typical MRI features (arrows): hyperintense on a T1-
weighted in-phase image (A) and marked signal loss on a T2-weighted fat-satu-
rated sequence (B). T1-weighted in-phase images (C and E) and out-of-phase
images (D and F) show undetermined lesions with the same SI as kidney with-
out the India ink sign in out-of-phase sequences. (C and D) show a lesion in the
posterior valve of the middle third of the left kidney (short arrow), (E and F)
show a lesion hanging from the lower pole (flat arrows). There were more
lesions with this atypical appearance in both kidneys (data not shown). The
lesion in the lower pole was biopsied and diagnosed as angiomyolipoma with
sclerosis and no visible fat. The other atypical lesions were also thought to be
atypical angiomyolipomas.
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assessed using CT angiography to identify active bleeding
points and obtain angiographic mapping.
Follow-up of patients treated with mTOR
inhibitors
mTOR inhibitors constitute a new approach to the manage-
ment of TSC-associated angiomyolipoma [44, 45]. The only
mTOR inhibitor approved for the treatment of renal angio-
myolipoma is everolimus, which is indicated in the treatment
of adult patients with TSC-associated angiomyolipoma who
are at risk of complications but do not need immediate sur-
gery [46]. Everolimus reduced tumour size in clinical trials [47,
48] and no kidney bleeding was observed during long-term
therapy [48]. Guidelines recommend initiating mTOR inhibi-
tor therapy in TSC patients who have at least one growing,
asymptomatic angiomyolipoma >3 cm in diameter [5].
Measurement of angiomyolipoma volume
Measurement of renal angiomyolipoma volume is useful for
follow-up and for assessing the effect of treatment on an indi-
vidual angiomyolipoma. Different methods can be used to cal-
culate angiomyolipoma volume. The borders of lesions can
sometimes be difficult to define because angiomyolipomas tend
to be convergent, heterogeneous and disorganized and their fat
component can be confused with perirenal and/or sinusal adi-
pose tissue.
The use of specialized volumetric software enables angio-
myolipoma volume to be calculated using various three-dimen-
sional (3D) techniques [49, 50]. However, these methods are not
suitable for routine examinations in daily practice because
image processing is time-consuming.
An easier alternative for estimating angiomyolipoma vol-
ume is the ellipsoid formula: p/6D1D2D3, where D1, D2
and D3 are the maximum diameters measured in 3D (Figure 3).
The panel recommends always using the same method and
keeping a register of the diameters obtained to compare with
future measurements.
Furthermore, TSC patients may have giant angiomyolipo-
mas and/or multiple convergent tumours that replace renal
parenchyma, thus preventing exact determinations of volume.
In such cases, response to therapy can be assessed by determin-
ing total kidney volume (Figure 4).
Radiology requests and reports
Due to the complexity of angiomyolipoma images, expert radiol-
ogists should be in charge of radiology reports. However, when
there is a possibility of reports being made by non-specialist radi-
ologists, radiology requests should be as detailed as possible.
Physicians should indicate why they are requesting a CT or
MRI examination. If the request is because the patient is experi-
encing pain, haematuria or any other specific reason, then
searching for bleeding is important. If CT or MRI is performed as
a routine examination, its main purpose is to measure the larger
angiomyolipomas (or the total kidney volume in some cases) to
evaluate either the impact of mTOR inhibitor therapy or the
course of the disease in untreated patients. When possible, pre-
vious images and radiology reports will help to assess this.
Based on their experience, the panel proposes a series of
essential points to be covered in radiology requests and reports
(Table 4).
Recommendations for first diagnosis (CT or MRI)
Radiology reports should include the following:
• Presence or absence of angiomyolipomas and any solid
lesion other than classic TSC-associated angiomyolipoma.
• Number and size of any angiomyolipomas with a diameter
>3 cm. If the angiomyolipomas are so numerous that they
cannot be assessed, the total kidney volume should be indi-
cated. An appropriate approximation is to calculate the ellip-
soid volume (see section above “Follow-up of patients
treated with mTOR inhibitors”).
Fig. 3. Contrast-enhanced CT coronal reconstruction and axial images showing
measurement of the three dimensions used to calculate angiomyolipoma vol-
ume based on the ellipsoid formula.
Fig. 4. Unenhanced CT images in the axial plane and sagittal reconstruction
show voluminous left-kidney angiomyolipomas that converge and virtually
replace renal parenchyma: measurement of total kidney volume is then the best
option since it is impossible to delimit individual lesions.




Size of bigger angiomyolipomas or total kidney volume
Presence of microaneurysms, especially those >5 mm
Follow-up Disease (TSC)
Reason for request: routine or new sign or symptom
Current therapy
Measurement of diameter of bigger angiomyolipomas or
extent of marked growth of any other angiomyolipoma
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• Presence or absence of microaneurysms within the angio-
myolipoma. Instances larger than 5 mm should be indicated.
• Presence or absence of acute or chronic intratumoural, peri-
renal and retroperitoneal bleeding. In the case of an emer-
gency radiology request resulting from a bleeding
angiomyolipoma, CT should be performed with multiplanar
reconstructions in the arterial and portal phases separately
if bleeding is to be treated with either embolization or
surgery.
• Presence or absence of cysts. Complicated cysts should be
assessed with enhanced or unenhanced CT or with MRI and
their size and location should then be described for further
monitoring.
• Presence or absence of fat-poor angiomyolipomas. If they
are indistinguishable from renal carcinomas or other poten-
tially malignant tumours, biopsy should be recommended to
confirm the diagnosis.
• When liver and/or spleen are included in the CT or MRI
examination, the presence or absence of hamartomas in
these organs must be assessed.
• When the lungs are partially visible in the CT or MRI exami-
nation, possible lung cysts should be assessed, especially in
women 18 years of age, because they are at risk for
lymphangioleiomyomatosis.
Interventional radiology
Embolization used to be the classic first-line therapy for prevent-
ing spontaneous bleeding of angiomyolipomas and for sympto-
matic angiomyolipomas [5]. Selective embolization was preferred
to nephrectomy because it preserves more of the renal paren-
chyma. It reduces angiomyolipoma volume and helps control
symptoms [51] but causes loss of healthy renal tissue.
Arteriography may be useful prior to embolization of actively
bleeding angiomyolipomas (Figure 5). Selective embolization is
not recommended as the first approach to management of TSC-
associated renal angiomyolipoma, mainly because these
tumours are usually bilateral and multifocal. Embolization proce-
dures should only be used in exceptional circumstances, such as
in acute bleeding [5].
Summary of panel recommendations
Table 5 shows the recommendations of the panel for diagnosis
and follow-up of TSC-associated renal angiomyolipoma.
Moreover, algorithms for the diagnosis of renal lesions in TSC
(Figure 6) and follow-up of untreated patients (Figures 7 and 8)
are provided.
Table 5. Recommendations for imaging assessment of renal angiomyolipomas associated with TSC
Diagnosis
• Ultrasonography is useful as an initial approach to determine the presence of kidney lesions and to determine whether these are solid or
cystic.
• The finding of macroscopic fat tissue usually confirms the radiological diagnosis of angiomyolipoma.
• Protocols for CT and MRI examinations are available.
• A hypointense renal mass on T2 that suppresses fat on the out-of-phase sequence is suggestive of isoattenuating fat-poor angiomyolipoma.
• If the diagnosis of angiomyolipoma is uncertain on CT or MRI, a percutaneous biopsy should be performed before surgery. If this biopsy is
not performed or all the tumours are thought to be angiomyolipomas, radiological surveillance is essential.
Monitoring
• MRI does not radiate and is preferred to CT for the surveillance of patients with known angiomyolipomas.
• Regular radiological monitoring is recommended to assess the risk of bleeding and the presence of tumours other than angiomyolipomas.
• In children, surveillance must be tailored to the radiological findings.
• In untreated adults, the frequency of follow-up examinations depends on the tumour size.
Therapy
• Imaging-based assessment of renal angiomyolipomas is mandatory to identify patients who can be treated with mTOR inhibitors and to
monitor the decrease and stabilization of these tumours in treated patients.
• CT is the test of choice for pre-surgical mapping or before embolization or resection.
• If an angiomyolipoma bleeds, urgent CT angiography is required and embolization may be needed.
• Radiologic interventional procedures with selective embolization should only be used in exceptional cases, such as in acute bleeding.
Fig. 5. Arteriography of an angiomyolipoma in the middle part of the right kid-
ney before selective embolization. The darker image corresponds to an intratu-
moural aneurysm.
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Conclusion
CT and MRI and their specific protocols are essential compo-
nents of imaging-based diagnosis and follow-up of TSC-
associated renal angiomyolipomas. Biopsy of renal masses can
be useful in exceptional cases. In addition, arteriography should
be used only prior to embolization of actively bleeding angio-
myolipomas. Our recommendations are intended as a tool for
the specialist care of patients with TSC-associated renal
angiomyolipomas.
Supplementary data
Supplementary data are available online at http://ckj.oxford
journals.org.
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